Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study

Abstract Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was assessed in PATENT–CHILD (NCT02562235), a multicent...

Full description

Bibliographic Details
Main Authors: Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice Beghetti
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Pulmonary Circulation
Subjects:
pediatrics
pharmacokinetics
pulmonary arterial hypertension
riociguat
treatment outcome
Online Access:https://doi.org/10.1002/pul2.12133

Internet

https://doi.org/10.1002/pul2.12133

Similar Items